ReviewHepatobiliary surgery and nutrition2022
Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review.
Review in Hepatobiliary surgery and nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- VPS33A Promotes Pemigatinib Resistance in Cholangiocarcinoma via Autophagy.Digestive diseases and sciences · 2026Article
- Lymphocyte to C-reactive protein ratio as a novel inflammatory biomarker: Validation and clinical relevance as an independent prognostic factor in cholangiocarcinoma.World journal of gastrointestinal oncology · 2025Article
- Cystatin B Promotes the Proliferation, Migration, and Invasion of Intrahepatic Cholangiocarcinoma.Current oncology (Toronto, Ont.) · 2025Article
- Targeted therapy for liver cancer: Current status and future directions.BioImpacts : BI · 2025Review
- Investigation of transcriptional and immunological disparities among patient groups with varied prognostic risk factors in cholangiocarcinoma.Cancer medicine · 2024Article
- Article
- Chemotherapy combined with targeted therapy and immunotherapy is an option in advanced biliary tract cancer.Therapeutic advances in gastroenterology · 2024Article
- Novel Adiponectin Receptor Agonist Inhibits Cholangiocarcinoma via Adenosine Monophosphate-activated Protein Kinase.Current medicinal chemistry · 2024Article
- Targeted therapies in hepatocellular carcinoma: past, present, and future.Frontiers in oncology · 2024Review
- Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version).Journal of clinical and translational hepatology · 2023Article
- Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.Cancer immunology, immunotherapy : CII · 2023Article
- Renin-angiotensin system inhibitors improve the survival of cholangiocarcinoma: a propensity score-matched cohort study.BMC cancer · 2023Article
- Targeted therapies in cholangiocarcinoma: light at the end of the tunnel?Hepatobiliary surgery and nutrition · 2023Article
- The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment.Hepatobiliary surgery and nutrition · 2023Article
- Exploring the function of stromal cells in cholangiocarcinoma by three-dimensional bioprinting immune microenvironment model.Frontiers in immunology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Cholangiocarcinoma is a highly aggressive and heterogenous group of biliary malignancies arising from any site in the biliary tree, comprising 15% of all primary liver cancers. The nature of the disease and nonspecific presentation leads to late diagnosis and ultimately poor outcomes for patients. Combination gemcitabine and cisplatin has been the standard of care for cholangiocarcinoma (CCA) since 2010, with a median overall survival of 11.7 months. The five-year survival for CCA remains 5-10%, revealing a clear need for improved treatment options. Methods: This targeted review highlights the role of next generation sequencing in CCA and the clinically relevant tumor biomarkers that have become the focus of therapeutic development. Key Content and Findings: These tumor biomarkers or actionable mutations hold the potential to enable earlier diagnosis, provide prognostic information, and guide treatment decisions for patients with CCA. Specifically, the Conclusion: The discovery of these actionable mutations and identification of targeted therapies have challenged the notion of a "one-size fits all" for treatment of CCA, and generated optimism that these novel treatments will soon be available for patients with CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.